News

Catalent announced a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeted at COVID-19. Under the terms of the agreement, Catalent will develop a…
Read More...

Boehringer Ingelheim and CDR-Life announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic…
Read More...

BioMed X, an independent research institute that identifies big biomedical research challenges and provides innovative solutions by combining global crowdsourcing with local incubation,…
Read More...

Cipla Limited announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine…
Read More...

CytoAgents announced that it has been awarded a National Institutes of Health (NIH) grant to accelerate the development of its lead drug candidate, GP1681, an investigational new drug…
Read More...

Skyhawk Therapeutics, Inc. announced that it has expanded its strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and…
Read More...

Legend Biotech Corporation announced that Legend and Noile-Immune Biotech, Inc. have entered into a license agreement whereby Legend will have the right to develop CAR-T and/or TCR-T…
Read More...

Glenmark Pharmaceuticals, a research-led integrated global pharmaceutical company, has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received…
Read More...

Seattle Genetics, Inc. announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA (tucatinib) tablets in combination with trastuzumab and…
Read More...

Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s mRNA vaccine candidate (mRNA-1273) against the novel…
Read More...

The Phase 3 IKEMA clinical trial evaluating Sarclisa (isatuximab) added to carfilzomib and dexamethasone met the primary endpoint at its first planned interim analysis, demonstrating…
Read More...

Ocular Therapeutix, Inc. announced that it has dosed the first patients in its Phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye…
Read More...

Bellerophon Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application, allowing the Company to initiate a…
Read More...

Themis, a clinical-stage biopharmaceutical company focused on immunomodulation therapies for infectious diseases and cancer, and ABL Europe (ABL), a global Contract Development and…
Read More...

CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation…
Read More...

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment…
Read More...

Dyno Therapeutics, Inc., a biotechnology company applying artificial intelligence (AI) to gene therapy, announced the company’s launch from stealth mode with its proprietary platform,…
Read More...

Acer Therapeutics Inc. announced it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS), one of the National…
Read More...

The U.S. Food and Drug Administration has issued the first emergency use authorization (EUA) for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic. These…
Read More...

Sorrento Therapeutics, Inc. and Mount Sinai Health System have agreed to join forces in the investigation and development of an antibody cocktail (COVI-SHIELD) to potentially treat…
Read More...